Alivus Life Sciences Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 5 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹16.3K Cr
Volume growth for Q3 FY'25 was strong at about 18%, despite a ~6% price erosion. Future growth is expected to be driven largely by new product launches; about 50% of revenue in 4-5 years is projected from new launches.
From Alivus Life Sciences Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,351
Market Cap
₹16.3K Cr
P/E Ratio
26.3
How does Alivus Life Sciences Ltd rank in Pharmaceuticals & Biotechnology?
Compare Alivus Life Sciences Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Alivus Life Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹689 Cr, net profit ₹163 Cr.
Full financials →📊 Revenue & Sales Performance
- →Volume growth for Q3 FY'25 was strong at about 18%, despite a ~6% price erosion.
- →CDMO business is expected to improve in coming quarters, though it shows cyclical demand. The 4th project has started but contribution is currently small, with more projects expected to commercialize by H1 FY'26.
- →Approximately half of revenue in 4-5 years is expected from new product launches, indicating significant growth from newer portfolios.
- →Stable demand from Europe, Japan, India, and Rest of World is offsetting weaker Americas (US & LATAM), with subdued demand expected in Americas for a couple more quarters.
- →Backward integration efforts are aimed at protecting margins and derisking raw materials supply, which should support stable future growth.
- →R&D investments to build new platforms are underway, aiming for commercialization starting early FY'27, indicating growth avenues beyond current portfolios.
- →Long-term growth driven by geographic diversification, new platforms, and new product pipelines.
📈 Profitability & Margins
- →Future growth is expected to be driven largely by new product launches; about 50% of revenue in 4-5 years is projected from new launches.
- →Competitive intensity remains high, but differentiation in quality, regulatory compliance, and service supports stable growth.
- →Investment in R&D and new platforms is underway, aiming to commercialize some projects by early FY'27 to fuel further growth.
- →CDMO business shows cyclical demand, with improvement expected from Q4 FY'25 onwards, though short-term growth may be uneven.
- →CAPEX plan includes greenfield expansion and R&D center investments totaling 400-500 crores over next 3-4 years, supporting capacity and innovation.
- →Despite modest price erosion (~4.5%-6%), volume growth remains strong (~18% in the recent quarter), supporting top-line and operating profit growth.
- →Operating margins have improved, with Q3 FY'25 EBITDA margin at 31.3% (up 90 bps YoY), indicating potential for margin expansion with better product mix.
🏗️ Capital Expenditure Plans
- →Ongoing greenfield expansion at Solapur; significant investment planned.
- →CAPEX for next 3-4 years projected at Rs. 400 to 500 crores.
- →Rs. 33 crores invested in the recent quarter; Rs. 119 crores over nine months FY'25.
- →New R&D center in progress; land securing underway.
- →Early R&D work started on new platforms aiming for commercialization by early FY'27.
- →Capital expenditure aligned with future growth and capacity expansion.
- →Cash on the balance sheet (~Rs. 499 crores) primarily earmarked for growth capital investments.
- →Dividend expected to continue but at lower levels compared to past years, with priority on reinvestment in business growth.
💰 Fundraising & Capital Structure
- →There is no explicit mention of any new fundraising through debt or equity in the provided transcript.
- →The company remains net debt-free as of December 31, 2024, with strong cash and cash equivalents of Rs.499 crores.
- →Planned capital expenditure for the next 3-4 years is well laid out at around Rs.400-500 crores for greenfield expansions and R&D facilities.
- →Surplus cash generated will primarily be used for growth capital investments and expansion projects.
- →Dividend payments may continue but at a lower level compared to past years, indicating a focus on reinvestment rather than returning cash to shareholders.
- →Transition costs and other one-time expenses are being incurred but no indication of raising external funds.
- →Overall, the company appears focused on using internal accruals and existing cash reserves to fund growth without new debt or equity issuance at this time.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Alivus Life Sciences Ltd Q3 FY25 results?
Volume growth for Q3 FY'25 was strong at about 18%, despite a ~6% price erosion. Future growth is expected to be driven largely by new product launches; about 50% of revenue in 4-5 years is projected from new launches.
What is Alivus Life Sciences Ltd share price analysis?
Alivus Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 26.3 with a market cap of ₹16,341 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alivus Life Sciences Ltd planning capital expenditure?
Ongoing greenfield expansion at Solapur; significant investment planned. - CAPEX for next 3-4 years projected at Rs.
Keep Alivus Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.